Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
▶︎
The Next Phase Of The Obesity Drug Race
▶︎
Eli Lilly CEO: How GLP-1s Will Reshape America
▶︎
How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company
▶︎
Feral Hogs: Last Week Tonight with John Oliver (HBO)
▶︎
Watch Ukrainian Drones OBLITERATE a Russian Jet
▶︎
Doku: Die geheime Welt des deutschen Adels
▶︎
I’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.
▶︎
Eli Lilly (LLY) Hits High After Diabetes Drug Approval
▶︎
Serena Williams and Oprah on Deciding to Take GLP-1 Medications
▶︎
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
▶︎
Golden Retriever Meets Completely Broken Rescue for the First Time
▶︎
Former ambassador on Ukrainian attacks in Russian-occupied Crimea
▶︎
Why Pharmaceuticals Are So Complicated In The U.S. | CNBC Marathon
▶︎
Eli Lilly CEO talks expanding innovation past obesity drugs
▶︎
This Is What Brexit Cost the World
▶︎
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
▶︎
Ozempic vs. Mounjaro | Which one actually protects you?
▶︎
AI Bubble Will Burst Eventually Says Bridgewater's Ray Dalio
▶︎
S13 E16: Iran Peace Deal & Feral Hogs: 6/21/26: Last Week Tonight with John Oliver
▶︎